



Pádraig O'Sullivan, T.D.
Dáil Éireann,
Leinster House,
Kildare Street,
Dublin 2.

1st June 2023

PQ: 26089/23

To ask the Minister for Health if he will outline the specific expenditure on new medicines and new uses of existing medicines in 2021 and 2022; if the information could be provided on an in-year basis and not solely on the projected five-year budget impact basis; and if he will make a statement on the matter. -Pádraig O'Sullivan

Dear Deputy O'Sullivan,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 26089/23), which you submitted to the Minister for Health for response.

The HSE approved a total of 52 drugs in 2021, of which 29 were new medicines and 23 are licence extensions/new uses of existing medicines. Of the 52 drugs approved, 39 drugs were funded from the €50m new drugs allocation.

The gross reimbursement by PCRS on 2021 New Drugs funded from the €50m Yr.1 new drug allocation was €34.4m in 2021 and €76.5m in 2022.

During 2022, a total of 60 new medicines were approved by the HSE, 30 of which are new medicines while 30 are licence extensions/new uses of existing medicines. 36 of these medicines were approved on a cost-minimisation basis relative to existing therapies (i.e. an uplift in pharmaceutical expenditure will not be incurred for those medicines as they have demonstrated budget neutrality). The remaining 24 of drugs approved fall within the €30m new drug allocation.

The gross reimbursement by PCRS in 2022 for 2022 New Drugs which fall into the €30m new drug allocation was €9.4m.

**** Source :- PCRS December 2022 Performance Report.**

Please note that not all 2021 & 2022 new drugs are reported in PCRS and all drugs dispensed may not be submitted for reimbursement within the calendar year.

PCRS does not collate data regarding Acute spending on 2021 and 2022 new drugs.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Suzanne Doyle', written over a faint horizontal line.

Suzanne Doyle
Primary Care Eligibility & Reimbursement Service